201 related articles for article (PubMed ID: 36410047)
1. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.
Bollu LR; Bommi PV; Monsen PJ; Zhai L; Lauing KL; Bell A; Kim M; Ladomersky E; Yang X; Platanias LC; Matei DE; Bonini MG; Munshi HG; Hashizume R; Wu JD; Zhang B; James CD; Chen P; Kocherginsky M; Horbinski C; Cameron MD; Grigorescu AA; Yamini B; Lukas RV; Schiltz GE; Wainwright DA
J Med Chem; 2022 Dec; 65(23):15642-15662. PubMed ID: 36410047
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.
Tang K; Wang B; Yu B; Liu HM
Eur J Med Chem; 2022 Jan; 227():113967. PubMed ID: 34752953
[TBL] [Abstract][Full Text] [Related]
3. Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Zhai L; Ladomersky E; Dostal CR; Lauing KL; Swoap K; Billingham LK; Gritsina G; Wu M; McCusker RH; Binder DC; Wainwright DA
Brain Behav Immun; 2017 May; 62():24-29. PubMed ID: 28179106
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
5. Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1.
Hu M; Zhou W; Wang Y; Yao D; Ye T; Yao Y; Chen B; Liu G; Yang X; Wang W; Xie Y
Acta Pharm Sin B; 2020 Oct; 10(10):1943-1953. PubMed ID: 33163345
[TBL] [Abstract][Full Text] [Related]
6. H
Yang D; Li T; Li Y; Zhang S; Li W; Liang H; Xing Z; Du L; He J; Kuang C; Yang Q
J Exp Clin Cancer Res; 2019 Feb; 38(1):88. PubMed ID: 30777103
[TBL] [Abstract][Full Text] [Related]
7. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K; Wu YH; Song Y; Yu B
J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
[TBL] [Abstract][Full Text] [Related]
10. 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.
Panda S; Pradhan N; Chatterjee S; Morla S; Saha A; Roy A; Kumar S; Bhattacharyya A; Manna D
Sci Rep; 2019 Dec; 9(1):18455. PubMed ID: 31804586
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH
Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246
[TBL] [Abstract][Full Text] [Related]
12. Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1.
Albini E; Coletti A; Greco F; Pallotta MT; Mondanelli G; Gargaro M; Belladonna ML; Volpi C; Bianchi R; Grohmann U; Macchiarulo A; Orabona C
Biochem Pharmacol; 2018 Dec; 158():286-297. PubMed ID: 30391205
[TBL] [Abstract][Full Text] [Related]
13. Discovery and biological evaluation of tanshinone derivatives as potent dual inhibitors of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase.
Liu J; Ren J; Yang K; Chen S; Yang X; Zhao QS
Eur J Med Chem; 2022 May; 235():114294. PubMed ID: 35358772
[TBL] [Abstract][Full Text] [Related]
14. The immunosuppressive role of indoleamine 2, 3-dioxygenase in glioblastoma: mechanism of action and immunotherapeutic strategies.
Hosseinalizadeh H; Mahmoodpour M; Samadani AA; Roudkenar MH
Med Oncol; 2022 Jun; 39(9):130. PubMed ID: 35716323
[TBL] [Abstract][Full Text] [Related]
15. Identification and Characterization of a Novel Dual Inhibitor of Indoleamine 2,3-dioxygenase 1 and Tryptophan 2,3-dioxygenase.
Yoshioka S; Ikeda T; Fukuchi S; Kawai Y; Ohta K; Murakami H; Ogo N; Muraoka D; Takikawa O; Asai A
Int J Tryptophan Res; 2022; 15():11786469221138456. PubMed ID: 36467776
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase 1 deficiency attenuates CCl4-induced fibrosis through Th17 cells down-regulation and tryptophan 2,3-dioxygenase compensation.
Zhong W; Gao L; Zhou Z; Lin H; Chen C; Huang P; Huang W; Zhou C; Huang S; Nie L; Liu Y; Chen Y; Zhou D; Lv Z
Oncotarget; 2017 Jun; 8(25):40486-40500. PubMed ID: 28465467
[TBL] [Abstract][Full Text] [Related]
17. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
18. Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
Fung SP; Wang H; Tomek P; Squire CJ; Flanagan JU; Palmer BD; Bridewell DJ; Tijono SM; Jamie JF; Ching LM
Bioorg Med Chem; 2013 Dec; 21(24):7595-603. PubMed ID: 24262887
[TBL] [Abstract][Full Text] [Related]
19. Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice.
Aslamkhan AG; Xu Q; Loughlin A; Vu H; Pacchione S; Bhatt B; Garfinkel I; Styring TG; LaFranco-Scheuch L; Pearson K; Reynolds S; Li N; Zhou H; Miller JR; Solban N; Bass A; Glaab WE
Toxicol Appl Pharmacol; 2020 Nov; 406():115216. PubMed ID: 32871117
[TBL] [Abstract][Full Text] [Related]
20. Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1.
Albini E; Rosini V; Gargaro M; Mondanelli G; Belladonna ML; Pallotta MT; Volpi C; Fallarino F; Macchiarulo A; Antognelli C; Bianchi R; Vacca C; Puccetti P; Grohmann U; Orabona C
J Cell Mol Med; 2017 Jan; 21(1):165-176. PubMed ID: 27696702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
